Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

United States118e CongrèsHR-3884House of Representatives
Mis à jour : 24 sept. 2024

Résumé

Aucun résumé n’est disponible.

Textes du projet de loi

Versions disponibles
Consulter le texte officiel

3 versions disponibles

Chronologie

Dernière mesure du projet de loi complémentaire

S-1852: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders without amendment. Without written report.

  1. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)

  2. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)

    House of Representatives

  3. Motion to reconsider laid on the table Agreed to without objection.

    House of Representatives

  4. Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Senate